Search 

BIOARRAY is a biotech company located at the Science park in New Haven. BIOARRAY is customizing treatments for patients to cure breast cancer the first time. BIOARRAY’s lead breast cancer test has been shown to reduce ineffective treatments by over 50% in proof of concept studies. BIOARRAY is a recipient of Avon Foundation and Connecticut Innovations funds. BIOARRAY is a MassChallenge Accelerator Winner.

Charles River discovery offers a truly integrated approach to small molecule drug discovery, uniting all of the key disciplines required to achieve a program's goals in a single project team. With the acquisition of BioFocus, Argenta and Chantest, the CRL Discovery organization can integrate medicinal chemistry, physical sciences, CADD, in vitro biology, HTS, structural biology, ADMET/PK and disease models as required.

Bionic Vision Technologies is the commercial entity which holds license to the patents around technology developed by Bionic Vision Australia.

Bionic Vision Australia brings together Australia’s leading experts in medical bionics to develop a bionic eye to restore vision to people with retinitis pigmentosa and age-related macular degeneration.  A prototype device has been successfully implanted into three patients for two years demonstrating outstanding safety and efficacy. 

Our capabilities which  differentiate us from competitors include:

1. Novel surgical techniques providing greater safety and stability od wide view devices

2. World leading, pioneering vision processing software

3. Unique arrangement and stimulation strategies of the electrodes

4. Unique diamond electrode encapsulation for the high acuity device

5. World leading psychophysics laboratory for assessing functionality of the devices

6. Unprecedented expertise and proven track record in preclinical studies

Our development portfolio consists of  wide view devices which aim to increase mobility and independence of patients and a high acuity device which will allow patients the ability to read large letters and recognise faces

Bionure is a late-preclinical company focused at developing First-in-Class SGK agonists for the treatment of orphan ophthalmological diseases.

Bionure's main candidate is BN201, a small molecule, new chemical entity, first-in-class drug that promotes neuroprotection and remyelination by means of a novel MOA.

Our main therapeutic focus is Optic Neuritis (ON), an acute, inflammatory disease of the optic nerve that qualifies for orphan status. BN201 has been granted orphan designation for the treatment of ON and the patent has been granted.

Preclinical efficacy studies have been performed in several animal models and a pre-IND meeting has been held with the FDA to validate our preclinical and clinical development. 

BN201 is now through the regulatory toxicology studies to enable IND by Q2 2015.

BioScience Managers is a venture capital life science investment firm headquartered in Melbourne, Australia. The group makes equity investments from $3M-5M and anticipates about 6 new investments this year. BioScience Managers invests globally. 

BioScience Managers will invest in companies across the life science space, including therapeutics, diagnostics and medical technology. The group does not invest in service providers. BioScience Managers considers all subsectors and indications, including orphan indications. The group will consider technology either in or prepared for human clinical trials and is open to all classes of devices. BioScience Managers seeks investments in novel technology and is not looking to gain share of an existing market. 

Biosight, LLC  is a start-up biomedical device company developing a low-cost technology that will enable health care providers (HCPs) to discriminate amongst different types of tissues so that they will no longer need to use the blind and semi-blind approach to procedural instrument placement. The key intellectual capital of Biosight, LLC, (Biosight) is medical procedure needle tip tissue identification using multimodal spectroscopy (MMS) technologies first developed in the Laser Biomedical Research Center (LBRC) at the Massachusetts Institute of Technology. Several founding members of Biosight are the pioneers in this field and have established collaborations with clinicians at the Massachusetts General Hospital to identify clinical areas for this technology. Currently, Biosight, LLC is working with several investors in Massachusetts to further develop the device for numerous clinical applications

Biosortia has opened the door to a new frontier of fascinating compounds that have the potential to materially impact the direction of various chronic diseases.  We are dedicated to discovering new chemical entities for the management of critical chronic disease states such as cancer, neuroscience, infectious disease, and inflammatory disorders to ultimately improve the lives of others.

Value Proposition

Pharma is looking for 3 key things:

1. Novel, never seen before, chemistry from new environments to fight chronic disease

2. Higher levels of potency (nano to Pico molar) to reduce the impact of side-effects

3. New mechanisms of action to fight chronic disease in new and more effective manner

It is well known that micro-organism consortia (not macro) are one of the most biologically active and chemically diverse plant/fungi that are rich in what we call “Defense Mechanism Chemistry”.  Defense Mechanism Chemistry is key in developing drugs for cancer, infectious disease and inflammation.  The problem is no one has been able to get access to this unique chemistry at scale and have the natural products expertise to identify the unique compounds…until now.  

We will provide Pharma with new compounds, rich in “Defense Mechanism Chemistry” on a routine basis that could shorten the discovery cycle by 2-3 years and reduce the overall cost.  

Best Regards,

Kurt Dieck

President and CEO

kdieck@biosortia.com

(614) 296-7076